SHR-8068, adebrelimab and bevacizumab added to TACE for incurable liver cancer
Tests adding SHR-8068, adebrelimab and bevacizumab to TACE in hepatocellular carcinoma.
Plain-language title generated from the registry record
Registry title: A Study of TACE in Combination With SHR-8068, Adebrelimab, and Bevacizumab Versus TACE in Participants With Incurable Hepatocellular Carcinoma
Key facts
- Where
- Nanjing and Shanghai, ChinaSee the 2 sites
- Phase
- Phase 3
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 75 years old?
Source: NCT07691762, who can take part
Where in China
- Zhongda Hospital Southeast UniversityNanjing, ChinaNo longer taking part
- Zhongshan Hospital,Fudan UniversityShanghai, ChinaNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Suzhou Suncadia Biopharmaceuticals Co., Ltd.
- Trial code
- NCT07691762
- Record updated
- 29 October 2026
- Original description
This is a multicenter, Phase 3 clinical trial to evaluate the efficacy and safety of SHR-8068, Adebrelimab, and Bevacizumab and TACE versus Placebo with TACE in incurable hepatocellular carcinoma.Read full original descriptionShow less
A Phase III, Randomized, Double-blind, Multicenter Study of SHR-8068 and Adebrelimab Plus Bevacizumab in Combination With TACE in Participants With Incurable Hepatocellular Carcinoma
This is a multicenter, Phase 3 clinical trial to evaluate the efficacy and safety of SHR-8068, Adebrelimab, and Bevacizumab and TACE versus Placebo with TACE in incurable hepatocellular carcinoma.
Participants will continue treatment until disease progresses, intolerable toxicity, withdrawal of informed consent, loss of follow-up, death, or other circumstances that require termination of treatment, whichever occurs first.
Inclusion: Age 18-75 years old, male or female; Diagnosis confirmed HCC by pathologically or clinically; At least one measurable lesion; Child-Pugh liver function grade A; ECOG-PS score: 0 or 1; Eligible for TACE treatment as assessed by the investigator; Participants with HBV or HCV infection must be on and remain on standard antiviral therapy throughout the study period; Consent to contraception.
Exclusion: Prior esophageal and/or gastric varices bleeding within 6 months prior to initiation of study treatment; Fibrolamellar hepatocellular carcinoma, sarcomatoid hepatocellular carcinoma or mixed cholangiocarcinoma / hepatocellular carcinoma; Participants with other malignancies currently or within the past 5 years; Participants with any active, known or suspected autoimmune disorder; Participants with hypertension which cannot be well controlled by antihypertensives; Uncontrolled cardiac diseases or symptoms; History of gastrointestinal perforation and/or fistula; Participants with hepatic encephalopathy; Participants with other potential factors that may affect the study results.